Oral semaglutide showed no effect on Alzheimer's progression
Awaiting primary-source check
The EVOKE and EVOKE+ trials, enrolling over 3,800 people across two years, found no difference in Alzheimer's disease progression. This is worth recording precisely because it is a negative result. GLP-1 drugs have been widely speculated about for conditions well beyond diabetes and weight, and most of those hypotheses will fail.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.